



1614
JRW

Case S-737-A
Appl. No. 10/197,077

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RAJENDRA K. JOSHI, ET AL.)
)
APPL. NO.: 10/197,077) GROUP ART UNIT: 1614
)
FILED: JULY 17, 2002) EXAMINER: KEVIN E. WEDDINGTON
)
UTILIZATION OF DIALKYL FUMARATES)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL AMENDMENT

Applicants desire to amend the above application by adding additional claims.

Amendments to the claims begin on page 2 hereof.

The Remarks commence on Page 7 hereof.

A Second Supplemental Information Disclosure Statement is also enclosed with the appropriate fee and a copy of the translated document referred to therein. Also enclosed is a paper authorizing the payment of the fee for the additional claims presented hereinafter.

11/29/2004 SMINASS1 00000001 502768 10197077

01 FC:1202	684.00 DA
02 FC:1201	352.00 DA

CERTIFICATE OF MAILING


I hereby certify that in accordance with standard business practice, this paper (along with any referred to as being attached or enclosed) is to be deposited on the date shown below with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Nov. 17, 2004
Date

Deborah A. Brouillette
Deborah A. Brouillette

In the Claims:


115. (New) A method for treating psoriasis comprising administering to a patient an effective amount of a pharmaceutical preparation which is in the form of microtablets or pellets and consists essentially of at least one dialkyl fumarate of the following formula



wherein R_1 and R_2 , which may be the same or different, independently represent a linear, branched or cyclic, saturated or unsaturated C_{1-20} alkyl radical which may be optionally substituted with halogen (Cl, F, I, Br), C_{1-4} alkoxy, nitro or cyano and optionally conventional excipients.

116. (New) A method as in claim 115, wherein said microtablets or pellets are contained in capsules.
117. (New) A method as in claim 115, wherein said preparation contains an amount between 10 and 300 mg of dimethyl fumarate.
118. (New) A method as in claim 115, wherein said preparation contains an amount of about 120 mg dimethyl fumarate.
119. (New) A method as in claim 115, wherein the size or mean diameter of said microtablets or pellets is in the range of 300 to 2000 μm .

120. (New) A method as in claim 115, wherein the size or mean diameter of said microtablets or pellets is about 2000 μm .
121. (New) A method as in claim 115, wherein said microtablets or pellets are enteric-coated and contained in capsules, and wherein said pharmaceutical preparation consists essentially of dimethyl fumarate in an amount between 10 and 300 mg.
122. (New) A method as in claim 121, wherein said pharmaceutical preparation consists essentially of dimethyl fumarate in an amount of about 120 mg.
123. (New) A method as in claim 121, wherein the size or mean diameter of said microtablets or pellets is in the range of 300 to 2000 μm .
124. (New) A method for treating multiple sclerosis comprising administering to a patient an effective amount of a pharmaceutical preparation which consists essentially of at least one dialkyl fumarate of the following formula



wherein R_1 and R_2 , which may be the same or different, independently represent a linear, branched or cyclic, saturated or unsaturated C_{1-20} alkyl radical which may be optionally substituted with halogen (Cl, F, I, Br), C_{1-4} alkoxy, nitro or cyano and optionally conventional excipients.

125. (New) A method as in claim 124, wherein said pharmaceutical preparation is in the form of microtablets or pellets.

126. (New) A method as in claim 125, wherein said microtablets or pellets are contained in capsules.
127. (New) A method as in claim 126, wherein said preparation contains an amount between 10 and 300 mg of dimethyl fumarate.
128. (New) A method as in claim 126, wherein said preparation contains an amount of about 120 mg dimethyl fumarate.
129. (New) A method as in claim 125, wherein the size or mean diameter of said microtablets or pellets is in the range of 300 to 2000 μm .
130. (New) A method as in claim 125, wherein the size or mean diameter of said microtablets or pellets is about 2000 μm .
131. (New) A method as in claim 125, wherein said microtablets or pellets are enteric-coated and are contained in capsules, and wherein said pharmaceutical preparation consists essentially of dimethyl fumarate in an amount between 10 and 300 mg.
132. (New) A method as in claim 131, wherein said pharmaceutical preparation consists essentially of dimethyl fumarate in an amount of about 120 mg.
133. (New) A method as in claim 131, wherein the size or mean diameter of said microtablets or pellets is in the range of 300 to 2000 μm .
134. (New) A pharmaceutical preparation in the form of enteric-coated microtablets or pellets containing dimethyl fumarate in an amount effective for treating psoriasis.
135. (New) The preparation of claim 134, wherein the microtablets or pellets are contained in capsules.

136. (New) The preparation of claim 135, wherein each capsule contains an amount between 10 and 300 mg of dimethyl fumarate.
137. (New) The preparation of claim 135, wherein each capsule contains an amount of about 120 mg dimethyl fumarate.
138. (New) The preparation of claim 134, wherein the size or mean diameter of said microtablets or pellets is in the range of 300 to 2000 μm .
139. (New) The preparation of claim 134, wherein the size or mean diameter of said microtablets or pellets is about 2000 μm .
140. (New) The preparation of claim 134, wherein the microtablets or pellets contain dimethyl fumarate in an amount between 10 and 300 mg.
141. (New) The pharmaceutical preparation of claim 140, wherein the microtablets or pellets contain dimethyl fumarate in an amount of about 120 mg.
142. (New) The preparation of claim 140 wherein the size or mean diameter of said microtablets or pellets is in the range of 300 to 2000 μm .
143. (New) A pharmaceutical preparation consisting essentially of dimethyl fumarate in an amount effective for treating multiple sclerosis.
144. (New) The preparation of claim 143, wherein the preparation is in the form of enteric-coated microtablets or pellets.
145. (New) The preparation of claim 144, wherein said microtablets or pellets are contained in capsules.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.